{"id":11421,"date":"2023-11-09T01:28:46","date_gmt":"2023-11-09T01:28:46","guid":{"rendered":"https:\/\/infundpros.com\/business\/approval-for-eli-lilly-obesity-drug-sets-up-rival-to-wegovy\/"},"modified":"2023-11-09T01:28:46","modified_gmt":"2023-11-09T01:28:46","slug":"approval-for-eli-lilly-obesity-drug-sets-up-rival-to-wegovy","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=11421","title":{"rendered":"Approval for Eli Lilly obesity drug sets up rival to Wegovy"},"content":{"rendered":"<div>\n<p>Stay informed with free updates<\/p>\n<p class=\"article__content-sign-up-topic-description\"><span>Simply sign up to the <!-- -->Pharmaceuticals sector<!-- --> myFT Digest &#8212; delivered directly to your inbox.<\/span><\/p>\n<p><iframe class=\"article__content-sign-up-iframe close\" scrolling=\"no\" id=\"signUpIframe\" data-prev-url=\"\/register\/in-article-sign-up?ft-content-uuid=66af86f2-547f-483e-adea-506373e00917&amp;concept-id=757b6406-5948-4bca-b352-37bdda7f90ac\"><\/iframe><\/div>\n<div id=\"article-body\">\n<p>Regulators on both sides of the Atlantic have cleared Eli Lilly\u2019s injectable diabetes medication for use as a weight loss treatment, creating the first direct rival to Wegovy, Novo Nordisk\u2019s obesity drug.<\/p>\n<p>The US Food and Drug Administration and the UK\u2019s Medicines and Healthcare products Regulatory Agency said patients in clinical trials of Lilly\u2019s tirzepatide had seen \u201csignificant\u201d weight loss compared with those given a placebo. At the highest dose, patients had lost nearly 50lbs on average, Lilly said.<\/p>\n<p>The regulators cleared the drug for weight-loss use for obese and overweight adults in conjunction with a lower-calorie diet and increased exercise.\u00a0Tirzepatide is already sold under the name Mounjaro as a diabetes treatment in both countries. It will keep that brand name in the UK as an obesity treatment but will be sold in the US as Zepbound for weight loss.<\/p>\n<p>About 70 per cent of adults in the US and 64 per cent in the UK are obese or overweight, according to the FDA and the House of Commons library. It contributes to some of the most common causes of death, such as heart disease, stroke and diabetes<\/p>\n<p>\u201cToday\u2019s approval addresses an unmet medical need,\u201d said John Sharretts, director of the diabetes and obesity division in the FDA\u2019s Center for Drug Evaluation and Research in a statement.\u00a0<\/p>\n<p>Steve Barclay, the UK health and social care secretary, hailed Mounjaro\u2019s potential to help cut waiting lists and save the National Health Service \u201cbillions of pounds\u201d.<\/p>\n<figure class=\"n-content-image n-content-image--inline\" style=\"width:300px;max-width:100%\"><picture><source media=\"(min-width: 700px)\"  width=\"300\" height=\"200\"><\/source><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/https:\/\/d1e00ek4ebabms.cloudfront.net\/production\/14f1ac28-deaa-4e71-90ab-a7a361eb6315.jpg\" alt=\"Eli Lilly\u2019s injectable weight loss drug Zepbound \" data-image-type=\"image\" width=\"300\" height=\"200\"><\/picture><figcaption class=\"n-content-picture__caption\"><span>Eli Lilly\u2019s injectable weight loss drug Zepbound <\/span><span> <!-- -->\u00a9 AP<\/span><\/figcaption><\/figure>\n<p>Tirzepatide will compete head on with Novo Nordisk\u2019s Wegovy, which has come to dominate the market for so-called GLP-1 weight-loss and diabetes management drugs with a 54.3 per cent global market share.\u00a0<\/p>\n<p>Tirzepatide is the first approved treatment that uses two agents, called dual agonists, including both GLP-1 and GIP. That made it more potent than Wegovy, said Fatima Cody Stanford, an obesity medicine physician and associate professor at Harvard Medical School and Massachusetts General Hospital.\u00a0<\/p>\n<p>\u201cThis new agent is the most efficacious of the [weight-loss drugs] we have seen so far,\u201d she said.<\/p>\n<p>Beverly Tchang, an obesity medicine physician at Weill Cornell Medicine and diplomate of the American Board of Obesity Medicine, said the medical community was \u201cextremely excited to have the official FDA approval of tirzepatide for the treatment of obesity\u201d. \u00a0<\/p>\n<p>\u201cThe only people more excited than we are my patients,\u201d she said. <\/p>\n<p>The side effects of Eli Lilly\u2019s and Novo Nordisk\u2019s obesity treatments are very similar, and patients could switch from one to the other, Stanford said. Studies show that, as with Wegovy, patients who stop taking tirzepatide see a quick rebound in weight.\u00a0<\/p>\n<p>Lilly expects to sell the new jab at a list price of nearly $1,060, but said this would be 20 per cent lower than Wegovy. David Risinger, a Leerink analyst, said in a note on Wednesday that the company had designed its pricing to encourage coverage in employers\u2019 health insurance plans. <\/p>\n<p>Novo Nordisk has struggled to meet the demand for Wegovy, leaving many patients facing supply issues that have interrupted their treatment for a month at a time in some cases, said Tchang. Interruptions led to weight gain and psychological challenges for patients who were meant to take the drug continuously, she said. <\/p>\n<p>\u00a0<\/p><\/div>\n<p>Read the full article <a href=\"https:\/\/www.ft.com\/content\/66af86f2-547f-483e-adea-506373e00917\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stay informed with free updates Simply sign up to the Pharmaceuticals sector myFT Digest &#8212; delivered directly to your inbox. Regulators on&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":{"0":"post-11421","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Approval for Eli Lilly obesity drug sets up rival to Wegovy | inFundPros<\/title>\n<meta name=\"description\" content=\"Stay informed with free updatesSimply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.Regulators on both sides of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=11421\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Approval for Eli Lilly obesity drug sets up rival to Wegovy | inFundPros\" \/>\n<meta property=\"og:description\" content=\"Stay informed with free updatesSimply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.Regulators on both sides of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=11421\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-09T01:28:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/https:\/\/d1e00ek4ebabms.cloudfront.net\/production\/14f1ac28-deaa-4e71-90ab-a7a361eb6315.jpg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=11421#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=11421\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"Approval for Eli Lilly obesity drug sets up rival to Wegovy\",\"datePublished\":\"2023-11-09T01:28:46+00:00\",\"dateModified\":\"2023-11-09T01:28:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=11421\"},\"wordCount\":584,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=11421#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=11421\",\"url\":\"https:\/\/infundpros.com\/?p=11421\",\"name\":\"Approval for Eli Lilly obesity drug sets up rival to Wegovy | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-11-09T01:28:46+00:00\",\"dateModified\":\"2023-11-09T01:28:46+00:00\",\"description\":\"Stay informed with free updatesSimply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.Regulators on both sides of\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=11421#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=11421\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=11421#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Approval for Eli Lilly obesity drug sets up rival to Wegovy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Approval for Eli Lilly obesity drug sets up rival to Wegovy | inFundPros","description":"Stay informed with free updatesSimply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.Regulators on both sides of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=11421","og_locale":"en_US","og_type":"article","og_title":"Approval for Eli Lilly obesity drug sets up rival to Wegovy | inFundPros","og_description":"Stay informed with free updatesSimply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.Regulators on both sides of","og_url":"https:\/\/infundpros.com\/?p=11421","og_site_name":"inFundPros","article_published_time":"2023-11-09T01:28:46+00:00","og_image":[{"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/https:\/\/d1e00ek4ebabms.cloudfront.net\/production\/14f1ac28-deaa-4e71-90ab-a7a361eb6315.jpg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=11421#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=11421"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"Approval for Eli Lilly obesity drug sets up rival to Wegovy","datePublished":"2023-11-09T01:28:46+00:00","dateModified":"2023-11-09T01:28:46+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=11421"},"wordCount":584,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=11421#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=11421","url":"https:\/\/infundpros.com\/?p=11421","name":"Approval for Eli Lilly obesity drug sets up rival to Wegovy | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-11-09T01:28:46+00:00","dateModified":"2023-11-09T01:28:46+00:00","description":"Stay informed with free updatesSimply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.Regulators on both sides of","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=11421#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=11421"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=11421#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"Approval for Eli Lilly obesity drug sets up rival to Wegovy"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11421"}],"version-history":[{"count":0,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/11421\/revisions"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}